文献速递临床试验与 GCP

益生菌补充与极早产儿坏死性小肠结肠炎及死亡风险——斯堪的纳维亚极早产儿益生菌(PEPS)试验:多中心、双盲、安慰剂对照、基于注册的随机对照试验研究方案

Probiotic supplementation and risk of necrotizing enterocolitis and mortality among extremely preterm infants-the Probiotics in Extreme Prematurity in Scandinavia (PEPS) trial: study protocol for a multicenter, double-blinded, placebo-controlled, and registry-based randomized controlled trial.
PubMed 文献 · Trials · 2024-04-12

PEPS试验为多中心、双盲、安慰剂对照、基于注册的随机对照试验,纳入瑞典6个和丹麦4个三级新生儿单位的极早产儿(n=1620),随机接受ProPrems®益生菌(含婴儿双歧杆菌、乳酸双歧杆菌和嗜热链球菌)或安慰剂(麦芽糊精粉)每日溶于3 mL母乳中至胎龄34周。主要复合结局为坏死性小肠结肠炎和/或死亡的发生率。

要点

  • 极早产儿(胎龄<28周)是坏死性小肠结肠炎和死亡的高危人群。
  • 既往益生菌随机对照试验在极早产儿中效力不足,证据不充分。
  • PEPS试验旨在提供足够效力的高质量证据以指导该人群益生菌补充指南。

核心结论

  • 该试验旨在研究益生菌补充对坏死性小肠结肠炎、死亡及其他相关结局的影响,以提供足够效力的高质量证据来指导该人群的益生菌补充指南。

研究设计与样本

  • 多中心、双盲、安慰剂对照、基于注册的随机对照试验,纳入瑞典6个和丹麦4个三级新生儿单位的极早产儿(n=1620)。
  • 纳入婴儿随机接受ProPrems®益生菌(含婴儿双歧杆菌、乳酸双歧杆菌和嗜热链球菌)溶于3 mL母乳或安慰剂(0.5 g麦芽糊精粉)溶于3 mL母乳,每日一次至胎龄34周。

主要发现

  • 主要复合结局为坏死性小肠结肠炎和/或死亡的发生率。
  • 次要结局包括晚发型脓毒症发生率、住院时长、抗生素使用、喂养耐受性、生长以及出院后足月龄和矫正月龄3个月时的体成分。

关键数值与推荐

  • 瑞典和丹麦现行益生菌补充推荐不包含极早产儿,因该人群缺乏证据。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Extremely preterm infants, defined as those born before 28 weeks' gestational age, are a very vulnerable patient group at high risk for adverse outcomes, such as necrotizing enterocolitis and death. Necrotizing enterocolitis is an inflammatory gastrointestinal disease with high incidence in this cohort and has severe implications on morbidity and mortality. Previous randomized controlled trials have shown reduced incidence of necrotizing enterocolitis among older preterm infants following probiotic supplementation. However, these trials were underpowered for extremely preterm infants, rendering evidence for probiotic supplementation in this population insufficient to date. METHODS: The Probiotics in Extreme Prematurity in Scandinavia (PEPS) trial is a multicenter, double-blinded, placebo-controlled and registry-based randomized controlled trial conducted among extremely preterm infants (n = 1620) born at six tertiary neonatal units in Sweden and four units in Denmark. Enrolled infants will be allocated to receive either probiotic supplementation with ProPrems® (Bifidobacterium infantis, Bifidobacterium lactis, and Streptococcus thermophilus) diluted in 3 mL breastmilk or placebo (0.5 g maltodextrin powder) diluted in 3 mL breastmilk per day until gestational week 34. The primary composite outcome is incidence of necrotizing enterocolitis and/or mortality. Secondary outcomes include incidence of late-onset sepsis, length of hospitalization, use of antibiotics, feeding tolerance, growth, and body composition at age of full-term and 3 months corrected age after hospital discharge. DISCUSSION: Current recommendations for probiotic supplementation in Sweden and Denmark do not include extremely preterm infants due to lack of evidence in this population. However, this young subgroup is notably the most at risk for experiencing adverse outcomes. This trial aims to investigate the effects of probiotic supplementation on necrotizing enterocolitis, death, and other relevant outcomes to provide sufficiently powered, high-quality evidence to inform probiotic supplementation guidelines in this population. The results could have implications for clinical practice both in Sweden and Denmark and worldwide. TRIAL REGISTRATION: ( Clinicaltrials.gov ): NCT05604846.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Kruth SS, Willers C, Persad E, et al. Probiotic supplementation and risk of necrotizing enterocolitis and mortality among extremely preterm infants-the Probiotics in Extreme Prematurity in Scandinavia (PEPS) trial: study protocol for a multicenter, double-blinded, placebo-controlled, and registry-based randomized controlled trial. Trials. 2024. PMID: 38610034. doi:10.1186/s13063-024-08088-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。